Show simple record

dc.contributor.authorVyas, Madhusudan
dc.contributor.authorFagan, Jessica
dc.date.accessioned2019-01-17T01:21:25Z
dc.date.available2019-01-17T01:21:25Z
dc.date.issued2018-09
dc.identifier.urihttps://hdl.handle.net/10652/4460
dc.description.abstractTheranostics Lu-177 : timeline Why Lu-177 is better Various Lu-177 labelled Radiopharmaceuticals in use Teaser for the future in New Zealanden_NZ
dc.language.isoenen_NZ
dc.subjectNeuroendocrine tumours (NETs)en_NZ
dc.subjectLu-177en_NZ
dc.subjectLutetium-177en_NZ
dc.subjecttheranosticsen_NZ
dc.subjectprostate canceren_NZ
dc.subjectradionuclide therapyen_NZ
dc.subjectNew Zealanden_NZ
dc.titleLu-177: a game-changeren_NZ
dc.typeConference Contribution - Oral Presentationen_NZ
dc.date.updated2018-12-14T13:30:05Z
dc.rights.holderAuthorsen_NZ
dc.subject.marsden1112 Oncology and Carcinogenesisen_NZ
dc.subject.marsden110313 Nuclear Medicine
dc.identifier.bibliographicCitationVyas, M. & Fagan, J. (2018, Sepetmber). Lu-177: A Game-changer. Paper presented at the ANZSNM- Annual Branch Meeting-2018, Invercargill,New Zealand.en_NZ
unitec.publication.titleANZSNM- Annual Branch Meeting-2018en_NZ
unitec.conference.titleANZSNM- Annual Branch Meeting-2018en_NZ
unitec.conference.orgAustralian and New Zealand Society of Nuclear Medicine (ANZSNM)en_NZ
unitec.conference.locationInvercargill,New Zealanden_NZ
unitec.conference.sdate2018-09-15
unitec.conference.edate2018-09-16
unitec.peerreviewedyesen_NZ
unitec.identifier.roms62837en_NZ


Files in this item

Thumbnail

This item appears in

Show simple record